| Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma (NCT04965454) | Queen's Medical Center | 2022-03-28 |
| Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma (NCT05114148) | UMC Utrecht | 2022-03-01 |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (NCT05717738) | Tongji Hospital | 2022-01-20 |
| Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC) (NCT04926376) | ABK Biomedical | 2021-11-02 |
| Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (NCT05031949) | Zhang Bi Xiang, MD | 2021-10-30 |
| Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy (NCT05057104) | Beijing 302 Hospital | 2021-10-10 |
| DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC (NCT04967482) | Second Affiliated Hospital of Guangzhou Medical University | 2021-07-09 |
| TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT (NCT04967495) | Second Affiliated Hospital of Guangzhou Medical University | 2021-07-09 |
| Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization (NCT05390112) | University Hospital, Rouen | 2021-05-20 |
| Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (NCT04718909) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-09 |
| Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC (NCT04522544) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-12-15 |
| Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment (NCT04511455) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-12-08 |
| TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors (NCT06487663) | Tianjin Medical University Cancer Institute and Hospital | 2020-10-27 |
| TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC (NCT04592029) | Second Affiliated Hospital of Guangzhou Medical University | 2020-10-21 |
| TACE Combined With Lenvatinib and Sintilimab for Advanced HCC (NCT04599790) | Second Affiliated Hospital of Guangzhou Medical University | 2020-10-01 |
| TACE Combined With Sorafenib and Tislelizumab for Advanced HCC (NCT04599777) | Second Affiliated Hospital of Guangzhou Medical University | 2020-10-01 |
| The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma (NCT04997850) | Xinrui Zhu，MD | 2020-10-01 |
| Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (NCT04224636) | Ludwig-Maximilians - University of Munich | 2020-06-10 |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (NCT05713994) | Ze-yang Ding, MD | 2020-05-19 |
| PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (NCT04273100) | Tianjin Medical University Cancer Institute and Hospital | 2019-11-14 |
| Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT (NCT06408753) | The University of Hong Kong | 2019-11-01 |
| Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT (NCT06265883) | Second Affiliated Hospital of Guangzhou Medical University | 2019-07-01 |
| Thermal Ablation Followed by Immunotherapy for HCC (NCT03864211) | Xiangya Hospital of Central South University | 2019-06-15 |
| Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma (NCT03881501) | Huazhong University of Science and Technology | 2019-03-05 |
| Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma (NCT03807947) | Humanitas Clinical and Research Center | 2019-01-01 |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) (NCT05543304) | First Affiliated Hospital of Wenzhou Medical University | 2018-12-01 |
| Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge (NCT03277716) | Fan Weijun | 2017-12-01 |
| Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma (NCT03533920) | Jeil Pharmaceutical Co., Ltd. | 2017-10-25 |
| Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (NCT03283956) | National Taiwan University Hospital | 2017-09-13 |
| HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients (NCT03379844) | UMC Utrecht | 2017-08-21 |
| Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma (NCT03138031) | The National Ribat University | 2017-05-01 |
| Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma (NCT03564405) | Jeil Pharmaceutical Co., Ltd. | 2016-12-05 |
| A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (NCT02989922) | Jiangsu HengRui Medicine Co., Ltd. | 2016-11-15 |
| Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC (NCT02967887) | CbsBioscience | 2016-11-01 |
| Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis (NCT04966195) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2015-12-01 |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) (NCT01009593) | Abbott | 2010-01-01 |